Human medicines European public assessment report (EPAR): Idacio, adalimumab, Date of authorisation: 02/04/2019, Revision: 14, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Nucala, Mepolizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immune system disorders, PIP number: P/0367/2024

Scientific recommendations on classification of advanced therapy medicinal products

European Platform for Regulatory Science Research meeting September 2025 , Online, European Medicines Agency, Amsterdam, the Netherlands, from 29 September 2025, 14:00 (CEST) to 29 September 2025, 17:30 (CEST)

Human medicines European public assessment report (EPAR): Gardasil, human papillomavirus vaccine [types 6, 11, 16, 18] (recombinant, adsorbed), Date of authorisation: 20/09/2006, Revision: 52, Status: Authorised

Human medicines European public assessment report (EPAR): Herwenda, trastuzumab, Date of authorisation: 15/11/2023, Revision: 2, Status: Authorised

Union Product Database (UPD) - questions and answers for industry users

Veterinary medicines European public assessment report (EPAR): MiPet Easecto, sarolaner, Status: Withdrawn

Human medicines European public assessment report (EPAR): Elevidys, delandistrogene moxeparvovec, Date of refusal: 24/09/2025, Status: Refused

Human medicines European public assessment report (EPAR): Imvanex, smallpox and monkeypox vaccine (Live Modified Vaccinia Virus Ankara), Date of authorisation: 31/07/2013, Revision: 31, Status: Authorised